Open Payments

Beaumont Health - Grosse Pointe

Type
Teaching hospital
Where
Grosse Pointe, MI
Medicare CCN
230089
Received
$3,396,751 in 131 records, 2024 ($2,917,753 general, $478,997 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment52$2,917,753
2024Research payment79$478,997

By company

CompanyRecordsAmountYears
Elekta, Inc.1$2,745,1332024
Boehringer Ingelheim Pharmaceuticals, Inc.5$145,5052024
United Therapeutics Corporation11$71,9382024
Ipsen Pharma SAS37$62,6762024
AngioDynamics, Inc.1$60,0002024
Elekta Limited1$58,3502024
IRONWOOD PHARMACEUTICALS, INC6$48,8662024
Medical Device Business Services, Inc.11$36,1362024
Janssen Pharmaceuticals, Inc1$25,0002024
Stryker Corporation7$18,1612024
Janssen Research & Development, LLC3$16,0522024
Boston Scientific Corporation9$15,6502024
SI-BONE, INC.3$12,7502024
Providence Medical Technology, Inc.2$11,2502024
Novartis Pharmaceuticals Corporation3$11,1002024
Roche TCRC, Inc.1$10,6302024
Smith+Nephew, Inc.4$10,4192024
Actelion Pharmaceuticals US, Inc.2$8,5002024
Abbott Laboratories3$7,0132024
Globus Medical, Inc.4$4,9002024
Eli Lilly and Company2$4,0972024
UCB, Inc.2$2,5002024
Novo Nordisk Inc2$2,5002024
National Marrow Donor Program4$2,4302024
Barco, Inc.1$1,3912024
Neurocrine BioSciences, Inc.1$1,2502024
Neurelis, Inc.1$1,2502024
Becton, Dickinson and Company1$5002024
MOLNLYCKE HEALTH CARE US, LLC1$5002024
MML US, Inc.1$3002024

By nature of payment

NatureRecordsAmount
Royalty or License1$2,745,133
Research payment79$478,997
Long term medical supply or device loan6$68,054
Space rental or facility fees (teaching hospital only)21$46,355
Compensation for services other than consulting, including serving as faculty or as a speaker at a v6$33,430
Grant15$23,450
Education1$1,250
Debt forgiveness2$80

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31AngioDynamics, Inc.$60,000Long term medical supply or device loanIn-kind items and servicesNanoKnife Device, Oncology Surgery2024
2024-12-31Stryker Corporation$1,886Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$1,832Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$1,832Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$1,111Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$40Debt forgivenessCash or cash equivalent2024
2024-12-31Stryker Corporation$40Debt forgivenessCash or cash equivalent2024
2024-12-24United Therapeutics Corporation$7,901Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-24United Therapeutics Corporation$2,592Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-24United Therapeutics Corporation$1,900Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-19Ipsen Pharma SAS$1,274Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-12-19Janssen Research & Development, LLC$250Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2024
2024-12-14SI-BONE, INC.$10,500Research paymentCash or cash equivalentIFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTIONPAULA2024
2024-12-09Medical Device Business Services, Inc.$2,318Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-06Stryker Corporation$11,417Research paymentCash or cash equivalentGAMMA Device, TRAUMA & EXTREMETIESPOST MARKET CLINICAL EVALUATION OF GAMMA 4: PROSPECTIVE, MULTICENTER, FOLLOW-UP STUDY (PEGASUS); CIP#: TA-01-20222024
2024-12-02Janssen Research & Development, LLC$15,552Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2024
2024-12-02United Therapeutics Corporation$9,896Research paymentCash or cash equivalentTYVASO Drug, Progressive Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2024
2024-11-28Ipsen Pharma SAS$2,495Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-11-28Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-11-26United Therapeutics Corporation$7,901Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-11-26UCB, Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-11-21Ipsen Pharma SAS$2,381Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-11-21Ipsen Pharma SAS$1,190Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-11-15Providence Medical Technology, Inc.$6,250Research paymentCash or cash equivalentFuse Study2024
2024-11-14Boston Scientific Corporation$2,000GrantIn-kind items and services Device, General - Stents_IC2024
2024-11-14Boston Scientific Corporation$2,000GrantIn-kind items and services Device, General - Stents_IC2024
2024-11-13UCB, Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-11-12IRONWOOD PHARMACEUTICALS, INC$22,142Research paymentCash or cash equivalentC3300-2012024
2024-11-09Novartis Pharmaceuticals Corporation$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentLEQVIO Drug, Cardiology/Vascular Diseases2024
2024-11-01Providence Medical Technology, Inc.$5,000Research paymentCash or cash equivalentFuse Study2024
2024-10-30United Therapeutics Corporation$5,796Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-10-30United Therapeutics Corporation$2,246Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-10-30Neurocrine BioSciences, Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentINGREZZA Drug, Neuropsychiatry2024
2024-10-25National Marrow Donor Program$200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-10-17Novartis Pharmaceuticals Corporation$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentLEQVIO Drug, Cardiology/Vascular Diseases2024
2024-10-09United Therapeutics Corporation$2,073Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-10-03Boston Scientific Corporation$2,500GrantIn-kind items and services Device, General - Structural Heart_IC2024
2024-10-01Actelion Pharmaceuticals US, Inc.$6,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentUPTRAVI Drug, Cardiology2024
2024-09-30Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-09-26Becton, Dickinson and Company$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-09-25United Therapeutics Corporation$23,958Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-09-25United Therapeutics Corporation$7,171Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-09-25United Therapeutics Corporation$500Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-09-20Boehringer Ingelheim Pharmaceuticals, Inc.$28,275Research paymentCash or cash equivalentBI 1015550 - Ph3 Open Label Extension2024
2024-09-19Barco, Inc.$1,391Long term medical supply or device loanIn-kind items and services2024
2024-09-18Ipsen Pharma SAS$2,912Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-09-18Ipsen Pharma SAS$1,961Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-09-18Ipsen Pharma SAS$1,303Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-09-18Ipsen Pharma SAS$1,274Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-09-18Neurelis, Inc.$1,250EducationCash or cash equivalentVALTOCO Drug, EPILEPSY2024
2024-09-18Ipsen Pharma SAS$1,190Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-09-17Novo Nordisk Inc$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-09-11Actelion Pharmaceuticals US, Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentOPSUMIT Drug, Cardiology2024
2024-08-26Ipsen Pharma SAS$1,961Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-08-22IRONWOOD PHARMACEUTICALS, INC$8,374Research paymentCash or cash equivalentC3300-2012024
2024-08-22Ipsen Pharma SAS$2,732Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-08-22Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-08-22Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-08-20Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-08-08MOLNLYCKE HEALTH CARE US, LLC$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentMepilex Border Sacrum Device, Wound Care2024
2024-08-01Janssen Research & Development, LLC$250Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2024
2024-07-31Ipsen Pharma SAS$1,000Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-07-26National Marrow Donor Program$615Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-07-19Roche TCRC, Inc.$10,630Research paymentCash or cash equivalentAntibiotics MCP patient PK study2024
2024-07-12Ipsen Pharma SAS$1,274Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-07-12Ipsen Pharma SAS$1,274Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-20Ipsen Pharma SAS$2,381Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-20Ipsen Pharma SAS$2,381Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-20Ipsen Pharma SAS$2,041Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-20Ipsen Pharma SAS$2,041Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-20Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-20Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-20Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-20Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-06-19Medical Device Business Services, Inc.$21,000Research paymentCash or cash equivalentVIVIGEN MIS DELIVERY SYSTEM Device, Spine TraumaClinical Outcomes Associated with the use of ViviGen in Conjunction with Posterolateral Fusion for the Treatment of Lumb2024
2024-06-06Boehringer Ingelheim Pharmaceuticals, Inc.$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-05-29Novo Nordisk Inc$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-05-27Medical Device Business Services, Inc.$804Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-05-22Elekta Limited$58,350Research paymentCash or cash equivalent2024
2024-05-20Elekta, Inc.$2,745,133Royalty or LicenseCash or cash equivalent2024
2024-05-13Medical Device Business Services, Inc.$3,713Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-05-06Abbott Laboratories$273Research paymentCash or cash equivalentAMPLATZER AMULET Device, STRUCTURAL HEARTAMPLATZER Amulet LAA Occluder Trial (Amulet IDE)2024
2024-05-03Boston Scientific Corporation$5,000GrantCash or cash equivalent Device, General - Therapies_EP2024
2024-04-26National Marrow Donor Program$800Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-04-25IRONWOOD PHARMACEUTICALS, INC$12,267Research paymentCash or cash equivalentC3300-2012024
2024-04-25Eli Lilly and Company$1,807Research paymentIn-kind items and servicesSUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUN2024
2024-04-22Medical Device Business Services, Inc.$1,350GrantCash or cash equivalent2024
2024-04-19Boston Scientific Corporation$250GrantIn-kind items and services Device, General - Therapies_EP2024
2024-04-11Medical Device Business Services, Inc.$1,350GrantCash or cash equivalent2024
2024-04-11Medical Device Business Services, Inc.$1,350GrantCash or cash equivalent2024
2024-04-02Globus Medical, Inc.$225Research paymentCash or cash equivalentBrigade Device, Spine/Spine SurgeryA prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patien2024
2024-04-01Smith+Nephew, Inc.$2,725Space rental or facility fees (teaching hospital only)Cash or cash equivalentQ-FIX Device, Sports Med Shoulder2024
2024-04-01Smith+Nephew, Inc.$2,484Space rental or facility fees (teaching hospital only)Cash or cash equivalentQ-FIX Device, Sports Med Shoulder2024
2024-03-29Boehringer Ingelheim Pharmaceuticals, Inc.$1,750Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-03-29Boston Scientific Corporation$1,750GrantIn-kind items and services Device, General - Therapies_PI2024
2024-03-27MML US, Inc.$300Research paymentCash or cash equivalentReActiv8 Device, Pain ManagementB Trial2024
2024-03-22Ipsen Pharma SAS$1,274Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-03-22Ipsen Pharma SAS$1,274Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-03-20Ipsen Pharma SAS$2,732Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-03-20Ipsen Pharma SAS$2,732Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-03-20Ipsen Pharma SAS$2,495Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-03-20Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-03-20Ipsen Pharma SAS$1,168Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-03-15Medical Device Business Services, Inc.$1,250GrantCash or cash equivalent2024
2024-03-11Medical Device Business Services, Inc.$1,250GrantCash or cash equivalent2024
2024-03-11Medical Device Business Services, Inc.$1,250GrantCash or cash equivalent2024
2024-03-08Boston Scientific Corporation$250GrantIn-kind items and services Device, General - Therapies_EP2024
2024-03-07Globus Medical, Inc.$1,850Research paymentCash or cash equivalentXLIF Device, Spine/Spine SurgeryNUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treat2024
2024-03-05Boehringer Ingelheim Pharmaceuticals, Inc.$72,720Research paymentCash or cash equivalentPDE4 Phase III trial in IPF patients2024
2024-03-05Boehringer Ingelheim Pharmaceuticals, Inc.$42,259Research paymentCash or cash equivalentPDE4 Phase III trial in PF-ILD2024
2024-02-27IRONWOOD PHARMACEUTICALS, INC$1,750Research paymentCash or cash equivalentC3300-2012024
2024-02-27IRONWOOD PHARMACEUTICALS, INC$500Research paymentCash or cash equivalentC3300-2012024
2024-02-21Ipsen Pharma SAS$1,190Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-02-15Globus Medical, Inc.$2,325Research paymentCash or cash equivalentXLIF Device, Spine/Spine SurgeryNUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treat2024
2024-02-15Globus Medical, Inc.$500Research paymentCash or cash equivalentXLIF Device, Spine/Spine SurgeryNUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treat2024
2024-02-11Novartis Pharmaceuticals Corporation$6,600Space rental or facility fees (teaching hospital only)Cash or cash equivalentENTRESTO Drug, Cardiology/Vascular Diseases2024
2024-02-09SI-BONE, INC.$1,650Research paymentCash or cash equivalentIFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2024
2024-02-07Smith+Nephew, Inc.$2,725Space rental or facility fees (teaching hospital only)Cash or cash equivalentQ-FIX Device, Sports Med Shoulder2024
2024-02-07Smith+Nephew, Inc.$2,484Space rental or facility fees (teaching hospital only)Cash or cash equivalentQ-FIX Device, Sports Med Shoulder2024
2024-02-05Medical Device Business Services, Inc.$500Research paymentCash or cash equivalentWaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF Mediated Stroke 22024
2024-02-02Boston Scientific Corporation$400GrantIn-kind items and services Device, General - Therapies_PI2024
2024-02-01IRONWOOD PHARMACEUTICALS, INC$3,831Research paymentCash or cash equivalentC3300-2012024
2024-01-29Eli Lilly and Company$2,289Research paymentIn-kind items and servicesEMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATI2024
2024-01-29Abbott Laboratories$740Research paymentCash or cash equivalentAMPLATZER AMULET Device, STRUCTURAL HEARTAMPLATZER Amulet LAA Occluder Trial (Amulet IDE)2024
2024-01-12National Marrow Donor Program$815Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-01-12SI-BONE, INC.$600Research paymentCash or cash equivalentIFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2024
2024-01-10Ipsen Pharma SAS$2,912Research paymentCash or cash equivalentDysport Drug, NeurologyA Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf2024
2024-01-10Ipsen Pharma SAS$2,142Research paymentCash or cash equivalentDysport Drug, NeurologyA Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf2024
2024-01-08Janssen Pharmaceuticals, Inc$25,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXARELTO Drug, Cardiovascular & Metabolism2024
2024-01-08Abbott Laboratories$6,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXIENCE ALPINE Device, Vascular2024
2024-01-05Boston Scientific Corporation$1,500GrantCash or cash equivalent Device, General - Catheter_IC2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyGrosse Pointe city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Grosse Pointe, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Grosse Pointe, MI
County
Wayne County, MI
State
Michigan
Population B010035,5411,772,25910,077,761
Population, 2020 census P15,6781,793,56110,077,331
Median age B0100243.837.940.2
Under 18 B0100126.6%23.6%21.2%
65 and over B0100123.2%16.6%18.6%
Households B110012,211700,5914,076,369
Foreign born B050027.8%10.3%7.2%
Median household income B19013$158,853$60,539$72,875
Median family income B19113$180,357$79,522$93,357
Per capita income B19301$86,088$34,906$40,735
Poverty rate B170012.8%20.8%13.2%
Unemployment rate B230254.3%8.7%5.7%
Civilian labor force B230252,769828,8385,018,449
Mean commute (minutes) B0801324.424.724.2
Bachelor's degree or higher B1500373.1%27.6%32.4%
Housing units B250012,452801,0834,622,236
Owner-occupied B2500385.9%64.8%73.2%
Renters B2500314.1%35.2%26.8%
Median home value B25077$436,800$178,500$231,600
Median gross rent B25064$1,725$1,132$1,129
White, not Hispanic B0300291.0%47.9%72.4%
Black B030021.5%36.6%13.1%
Hispanic or Latino B030023.1%6.9%5.9%
Asian B030021.0%3.7%3.4%
American Indian and Alaska Native B030020.1%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Grosse Pointe, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.